In the Claims:

54. (Currently amended) A compound according to the formula:



Wherein B is  or  ;

R is H, F, Cl, Br, I, C_1-C_4 alkyl, -C≡N, -C≡C-R_a,  or  ;

X is H, C_1-C_4 alkyl, F, Cl, Br or I;

R^1 is H, an acyl group, a C_1—C_{20} alkyl or an ether group;

R^2 is H, an acyl group, a C_1—C_{20} alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a

 or  group;

Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R^8 is H or a C_1-C_{20} alkyl or ether group;

R^3 is a C_1, C_3 or C_4 alkyl group, $-(CH_2)_n$-C≡C-R_a,  or 

when B is  and

R^3 is C_1-C_4 alkyl, $-(CH_2)_n$-C≡C-R_a,  or  when B is


;

R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or -C_1-C_4 alkyl;

Y is H, F, Cl, Br, I or -C_1-C_4 alkyl; and

k is ~~0, 1 or 2~~ 0-12;

n is 0, 1, 2,3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.

55. (Currently amended) The compound according to claim 54 wherein B is



and k is 0, 1 or 2.

56. (Previously Presented) The compound according to claim 55 wherein R^3 is

$-(CH_2)_n-C\equiv C-R_a$,  or 

57. (Previously Presented) The compound according to claim 56 wherein R is F, Cl, Br, I, C_1-C_3 alkyl,

$-C\equiv C-R_a$,  or  and X is H, C_1-C_4 alkyl, F, Cl, Br or I.

58. (Previously Presented) The compound according to claim 56 wherein R is CH_3, R^3 is $-(CH_2)_n-C\equiv C-R_a$, n is 0 and R_a is H.

59. (Previously Presented) The compound according to claim 58 wherein R^{3a} and R^{3b} are both H.

60. (Previously Presented) The compound according to claim 58 wherein R^2 is H.

61. (Previously Presented) The compound according to claim 54 which is



62. (Previously Presented) The compound according to claim 61 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

63. (Previously Presented) The compound according to claim 61 wherein R^2 is H.

64. (Currently amended) The compound according to claim 54 wherein B is



and k is 0, 1 or 2.

65. (Previously Presented) The compound according to claim 64 wherein R^3 is CH_3, $-(CH_2)_n-C\equiv C-R_a$,  and n is 0.

66. (Previously Presented) The compound according to claim 65 wherein R is H, F, Cl, Br, I, CH_3, $-C\equiv C-R_a$,  and X is H, C_1-C_4 alkyl, F, Cl, Br or I.

67. (Previously Presented) The compound according to claim 64 wherein R is CH_3, R^3 is $-(CH_2)_n$-C≡C-R_a, n is 0 and R_a is H.

68. (Previously Presented) The compound according to claim 67 wherein R^{3a} and R^{3b} are both H.

69. (Previously Presented) The compound according to claim 68 wherein R^2 is H.

70. (Currently amended) A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:



Wherein B is  or  ;

R is H, F, Cl, Br, I, C_1-C_4 alkyl, -C≡N, -C≡C-R_a,  ;

X is H, C_1-C_4 alkyl, F, Cl, Br or I;

R^1 is H, an acyl group, a C_1—C_{20} alkyl or an ether group;

R^2 is H, an acyl group, a C_1—C_{20} alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



or



group;

Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R^8 is H or a C_1-C_{20} alkyl or ether group;

R^3 is a C_1, C_3 or C_4 alkyl group, $-(CH_2)_n-C\equiv C-R_a$,  or 

when B is  and

R^3 is C_1-C_4 alkyl, $-(CH_2)_n-C\equiv C-R_a$,  or  when B is



;

R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or -C_1-C_4 alkyl;

Y is H, F, Cl, Br, I or -C_1-C_4 alkyl;

k is ~~0, 1 or 2~~ 0-12; and

n is 0, 1, 2,3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.

71. (Previously Presented) The composition according to claim 70 wherein B is



and k is 0, 1 or 2.

72. (Previously Presented) The composition according to claim 71 wherein R^3 is

$-(CH_2)_n$-C≡C-R_a,  or

73. (Previously Presented) The composition according to claim 72 wherein R is F, Cl, Br, I, C_1-C_3 alkyl,

-C≡C-R_a,  or  and X is H, C_1-C_4 alkyl, F, Cl, Br or I.

74. (Previously Presented) The composition according to claim 71 wherein R is CH_3, R^3 is $-(CH_2)_n$-C≡C-R_a, n is 0 and R_a is H.

75. (Previously Presented) The composition according to claim 74 wherein R^{3a} and R^{3b} are both H.

76. (Previously Presented) The composition according to claim 75 wherein R^2 is H.

77. (Previously Presented) The composition according to claim 70 wherein said compound is



78. (Previously Presented) The composition according to claim 77 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

79. (Previously Presented) The composition according to claim 77 wherein R^2 is H.

80. (Currently amended) The composition according to claim 70 wherein B is



and k is 0, 1 or 2.

(Previously Presented) The composition according to claim 80 wherein R^3 is CH_3,

$-(CH_2)_n-C\equiv C-R_a$,  and n is 0.

81. (Previously Presented) The composition according to claim 81 wherein R is H, F, Cl, Br, I, CH_3,

$-C\equiv C-R_a$,  and X is H, C_1-C_4 alkyl, F, Cl, Br or I.

83. (Previously Presented) The composition according to claim 80 wherein R is CH_3, R^3 is $-(CH_2)_n-C\equiv C-R_a$, n is 0 and R_a is H.

84. (Previously Presented) The composition according to claim 83 wherein R^{3a} and R^{3b} are both H.

85. (Previously Presented) The composition according to claim 84 wherein R^2 is H.

86. (Previously Presented) The composition according to claim 70 wherein said compound is



Where R^1 is H or an acyl group; and

R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

87. (Previously Presented) The composition according to claim 86 wherein R^1 is H and R^2 is H.